Mark Breidenbach
Stock Analyst at Oppenheimer
(1.28)
# 3,688
Out of 5,111 analysts
52
Total ratings
30.91%
Success rate
-0.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.51 | +363.58% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $19.07 | +57.32% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $12.58 | +655.17% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.08 | +311.18% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.49 | +1,952.97% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $16.94 | +1,316.77% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.31 | +4,733.84% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.53 | +357.52% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.79 | +1,687.71% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.20 | +581.82% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.11 | +10,710.81% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.20 | +815,799.58% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.51
Upside: +363.58%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $19.07
Upside: +57.32%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $12.58
Upside: +655.17%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.08
Upside: +311.18%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.49
Upside: +1,952.97%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $16.94
Upside: +1,316.77%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.31
Upside: +4,733.84%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.53
Upside: +357.52%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.79
Upside: +1,687.71%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.20
Upside: +581.82%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.11
Upside: +10,710.81%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.20
Upside: +815,799.58%